| 2.14 -0.04 (-1.83%) | 12-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.73 | 1-year : | 3.19 |
| Resists | First : | 2.33 | Second : | 2.73 |
| Pivot price | 2.09  |
|||
| Supports | First : | 1.93 | Second : | 1.68 |
| MAs | MA(5) : | 2.16 |
MA(20) : | 2.02 |
| MA(100) : | 1.8 |
MA(250) : | 2.94 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 68.1 |
D(3) : | 74.1 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 8.4 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMRX ] has closed below upper band by 37.7%. Bollinger Bands are 45.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.24 - 2.25 | 2.25 - 2.26 |
| Low: | 2.04 - 2.06 | 2.06 - 2.07 |
| Close: | 2.12 - 2.14 | 2.14 - 2.16 |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Wed, 27 Nov 2024
Immuneering to Present Pipeline and Strategy at Piper Sandler Healthcare Conference | IMRX Stock News - StockTitan
Wed, 20 Nov 2024
Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Target Price from Brokerages - MarketBeat
Fri, 15 Nov 2024
Immuneering Corp. Reports Q3 Loss, Highlights Progress - TipRanks
Wed, 13 Nov 2024
Immuneering Reports Promising Cancer Drug Results, Secures FDA Fast Track Status - StockTitan
Sat, 26 Oct 2024
Immuneering Slides As Insider Purchases Lose Another US$82k - Simply Wall St
Mon, 14 Oct 2024
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 29.1 (%) |
| Held by Institutions | 30.1 (%) |
| Shares Short | 2,050 (K) |
| Shares Short P.Month | 1,630 (K) |
| EPS | -1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.5 % |
| Return on Equity (ttm) | -61.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -1.09 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|